Darė Ovaprene to Start Trial

$Dare Bioscience(DARE.US)$ is gearing up to launch its study of Ovaprene, a monthly hormone free women's contraceptive that they have partnership with $BAYER AG(BAYRY.US)$ on. They announced that the FDA has approved the study and expect to enroll mid-2023.

Darė already has FDA approval for Xaciato with which they announced a partnership with $Organon & Co(OGN.US)$ and expect revenues to begin generating in Q4 2022.